Using celecoxib for pain management after parotid surgery
Celecoxib Pain Management Following Superficial Parotidectomy: Opioid Sparing Protocol
This study is testing if taking celecoxib with Tylenol can help manage pain after parotid surgery and reduce the need for stronger painkillers like oxycodone.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06505187 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates whether celecoxib, combined with Tylenol, can effectively manage pain after parotidectomy, potentially reducing the need for oxycodone. Participants will be randomly assigned to receive either celecoxib or a placebo alongside Tylenol, while keeping a diary of their pain levels and completing questionnaires throughout the study. The goal is to determine if this approach can minimize opioid prescriptions and associated risks in postoperative care.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are scheduled for superficial parotidectomy and can comply with study procedures.
Not a fit: Patients with a history of contraindications to NSAIDs or those with certain cardiovascular or gastrointestinal conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safer pain management alternative that reduces reliance on opioids for patients undergoing parotid surgery.
How similar studies have performed: Other studies have shown promise in using non-opioid analgesics for postoperative pain management, suggesting this approach may be viable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Willing to comply with all study procedures and be available for the duration of the study * Ability to take oral medication * Undergoing superficial parotidectomy * Individuals at least 18 years of age * Adequate organ function as indicated by standard laboratory tests: hematology (complete blood count), clinical chemistry Exclusion Criteria: * History of NSAIDs contraindication (severe congestive heart failure, CABG within 14 days, arrhythmias, significant coronary artery disease, cardiomyopathy, severe hepatic impairment, history of peptic ulcer disease or GI bleeding, use of anticoagulation (other than prophylactic aspirin) * History of uncontrolled hypertension, cerebrovascular accident, sulfa allergy, allergy to celecoxib * Concurrent use of CYP2C9 potentiator/inhibitor * Use of investigational drugs, biologics, or devices within 30 days prior to randomization. * Individuals who are pregnant, lactating or planning on becoming pregnant during the study. * Not suitable for study participation due to other reasons at the discretion of the investigators.
Where this trial is running
Madison, Wisconsin
- University of Wisconsin — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Tiffany Glazer, MD — University of Wisconsin, Madison
- Study coordinator: Hayley Mann, MD
- Email: hmann3@wisc.edu
- Phone: 480-272-4258
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.